Global Prostate Cancer Therapeutics Market (2010 – 2020) (Opportunity Analysis, Pipeline Assessment & Market Forecast)

• Publication date: November 2011

Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost. This report studies t...

Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.

This report studies the market from 2005 to 2020 covering 21 major drugs categorized into four therapies; namely hormonal therapy, chemotherapy, immunotherapy, and targeted therapy. Out of the whole lot of 21 drugs, 13 are currently commercially available in the market and 8 in pipeline. Growing prostate cancer population (25% increase in the incidence of prostate cancer in mature countries and 40% increase in emerging countries, from 2010 to 2020) is an impetus for the growth of the market. This factor, along with increasing number of innovative drugs estimated to get launched in short-term future and increasing old age male population are driving the growth of the market at an expected CAGR of 9% from 2010 to 2020. In 2010, among the mature markets, the U.S. was the major contributor; accounting for 35% of the total sales of prostate cancer drugs and amongst the emerging countries, China contributed to the share of about 2% of the overall prostate cancer therapeutics market.

As far as drugs are concerned, Taxotere accounted for 23% of the total sales of prostate cancer drugs in 2010. Astrazeneca PLC is the leading market player with the share of 30% in the total prostate cancer therapeutics market, in 2010. However, by 2020, Astrazeneca will lose its market share by 19%, due to entry of new players such as Active Biotech, Bristol Myers-Squibb, Teva Pharmaceuticals Industries Ltd, and Johnson & Johnson (entered the market in 2011, with its key drug Zytiga).

Players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were certain major strategies adopted by the players from January 2006 to September 2011.

Scope of the report 

The prostate cancer therapeutics market research report evaluates the global prostate cancer drugs market with respect to the current and pipeline drugs. The report analyzes geography; forecasting revenue, and trends in each of the following submarkets:

Global prostate cancer hormonal therapy drugs market - 

LHRH antagonists - Firmagon 
LHRH analogs - Zoladex, Lupron, Eligard, Vantas, and Decapeptyl 
Antiandrogens - Casodex 
Pipeline drugs for hormonal therapy - Zytiga, MDV3100, and TAK700 
Global prostate cancer chemotherapy drugs market - 

Off patent drugs - Taxotere, mitoxantrone, and Emcyt 
Patented drugs - Jevtana 
Global prostate cancer immunotherapy drugs market- 

Patented drug - Provenge 
Pipeline drug - ipilimumab 
Global prostate cancer targeted therapy drugs market- 

Angiogenesis inhibitor - lanreotide, TASQ, Zaltrap 
Apoptosis inducing - custirsen sodium 
Signal transduction inhibitor - Sprycel 
The geographies covered under the report are -

North America 

U.S. 
Canada 
Europe

U.K. 
Germany 
Italy 
France 
Spain 
Emerging countries

Brazil 
Russia 
India 
China 
Turkey 
South Korea 
Each section provides market data, market drivers, trends and opportunities, key players, and competitive outlook. This report also provides market tables for covering the sub-segments and micro-markets. Additionally, it makes ways for company profiles that cover all the sub-segments. The report has been made by keeping past trends, current happenings, and future forecasts in consideration.

Therapy Industry

TABLE OF CONTENTS

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW
3.1 DEFINING PROSTATE CANCER
3.1.1 RISK FACTORS
3.1.1.1 Age
3.1.1.2 Race
3.1.1.3 Family history/genetics
3.1.1.4 Diet/lifestyle factors
3.1.1.5 Obesity
3.1.1.6 Infection/Inflammation of the prostate gland
3.1.2 DISEASE SYMPTOMS
3.1.3 DIAGNOSIS
3.1.3.1 Digital rectal exam (DRE)
3.1.3.2 Prostate specific antigen (PSA) blood test
3.1.3.3 Prostate biopsy
3.1.3.4 Ultrasound
3.1.3.5 Bone scan
3.1.3.6 CT scan & MRI
3.1.3.7 PET & SPECT scan
3.1.3.8 Lymph node biopsy
3.1.3.9 ProstaScint monoclonal antibody scan
3.1.4 PROSTATE CANCER PREVALENCE
3.1.5 INCIDENCE & MORTALITY
3.2 STAGES OF PROSTATE CANCER
3.2.1 STAGE I
3.2.2 STAGE II
3.2.3 STAGE III
3.2.4 STAGE IV
3.3 MARKET STRUCTURE
3.3.1 KEY THERAPIES
3.3.1.1 Chemotherapy
3.3.1.2 Hormonal therapy
3.3.1.3 Immunotherapy
3.3.1.4 Targeted therapy

4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INNOVATIVE DRUGS DRIVING THE MARKET
4.2.2 INCREASE IN RESEARCH & DEVELOPMENT IN ONCOLOGY THERAPEUTIC AREA
4.2.3 DEVELOPMENTS IN GENOMICS & PROTEOMICS
4.3 RESTRAINTS
4.3.1 ADVERSE EVENTS OF TREATMENT
4.3.2 COST ASSOCIATED WITH THE TREATMENT
4.3.3 INCREASING ADOPTION OF VALUE BASED MEDICINE CONCEPT IN MAJOR MARKETS
4.3.4 LOW SUCCESS RATE IN CLINICAL TESTING FOR ONCOLOGY DRUGS
4.4 OPPORTUNITIES
4.4.1 LIMITED PLAYERS IN THE MARKET
4.4.2 GROWING OLDER MALE POPULATION
4.4.3 OFF LABEL PRESCRIPTION FOR PROSTATE CANCER
4.4.4 TREND OF INCREASE IN PHARMACEUTICAL EXPENDITURE BY EMERGING MARKETS
4.4.5 ONCOLOGY IS THE LARGEST THERAPEUTIC MARKET WITH HIGH UNMET NEEDS
4.5 MARKET SHARE
4.5.1 BY COMPANY
4.5.2 BY GEOGRAPHY
4.5.3 BY THERAPY
4.6 BURNING ISSUES
4.6.1 HIGH COST OF TREATMENT RELATIVE TO MODEST DRUG BENEFIT
4.6.2 ESTIMATED INCREASE IN COMPETITION DUE TO ADDITION OF PROSTATE CANCER INDICATION TO EXISTING DRUGS
4.7 WINNING IMPERATIVES
4.7.1 STRATEGY OF GEOGRAPHICAL EXPANSION IN EMERGING MARKETS
4.7.2 STRATEGY OF PRODUCT EDUCATION COUPLED WITH PRODUCTION CAPACITY EXPANSION

5 PRODUCT MARKET
5.1 HORMONAL THERAPY
5.1.1 LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANTAGONISTS
5.1.1.1 FIRMAGON
5.1.2 LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOGS
5.1.2.1 LUPRON
5.1.2.2 ZOLADEX
5.1.2.3 DECAPEPTYL
5.1.2.4 ELIGARD
5.1.2.5 VANTAS
5.1.3 ANTI-ANDROGENS
5.1.3.1 CASODEX
5.2 CHEMOTHERAPY
5.2.1 TAXOTERE
5.2.2 JEVTANA
5.2.3 MITOXANTRONE (NOVANTRONE)
5.2.4 ESTRAMUSTINE (EMCYT)
5.3 IMMUNOTHERAPY
5.3.1 PROVENGE

6 PIPELINE DRUGS MARKET
6.1 HORMONAL THERAPY
6.1.1 ABIRATERONE ACETATE
6.1.2 MDV3100
6.1.3 TAK700
6.2 TARGETED THERAPY
6.2.1 ANGIOGENESIS INHIBITORS
6.2.1.1 LANREOTIDE
6.2.1.2 TASQUINIMOD (TASQ)
6.2.1.3 ZALTRAP
6.2.2 APOPTOSIS INDUCING
6.2.2.1 CUSTIRSEN SODIUM
6.2.3 SIGNAL TRANSDUCTION INHIBITOR
6.2.3.1 SPRYCEL
6.3 IMMUNOTHERAPY
6.3.1 IPILIMUMAB

7 GEOGRAPHICAL ANALYSIS
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.2.1 U.S.
7.2.2 CANADA
7.3 EUROPE
7.3.1 U.K.
7.3.2 GERMANY
7.3.3 FRANCE
7.3.4 ITALY
7.3.5 SPAIN
7.4 JAPAN
7.5 EMERGING MARKETS
7.5.1 BRAZIL
7.5.2 RUSSIA
7.5.3 INDIA
7.5.4 CHINA
7.5.5 TURKEY
7.5.6 SOUTH KOREA

8 COMPETITIVE LANDSCAPE
8.1 KEY STRATEGIES

9 COMPANY PROFILES
9.1 ABBOTT LABORATORIES
9.1.1 OVERVIEW
9.1.2 PRODUCTS & SERVICES
9.1.3 FINANCIALS
9.1.4 STRATEGY
9.1.5 DEVELOPMENTS
9.2 ACTIVE BIOTECH
9.2.1 OVERVIEW
9.2.2 PRODUCTS & SERVICES
9.2.3 FINANCIALS
9.2.4 STRATEGY
9.2.5 DEVELOPMENTS
9.3 ASTRAZENECA PLC
9.3.1 OVERVIEW
9.3.2 PRODUCTS & SERVICES
9.3.3 FINANCIALS
9.3.4 STRATEGY
9.3.5 DEVELOPMENT
9.4 ASTELLAS PHARMA INC
9.4.1 OVERVIEW
9.4.2 PRODUCTS & SERVICES
9.4.3 FINANCIALS
9.4.4 STRATEGY
9.4.5 DEVELOPMENTS
9.5 BRISTOL-MYERS SQUIBB
9.5.1 OVERVIEW
9.5.2 PRODUCTS & SERVICES
9.5.3 FINANCIALS
9.5.4 STRATEGY
9.5.5 DEVELOPMENTS
9.6 DENDREON CORPORATION
9.6.1 OVERVIEW
9.6.2 PRODUCTS & SERVICES
9.6.3 FINANCIALS
9.6.4 STRATEGY
9.6.5 DEVELOPMENTS
9.7 ENDO PHARMACEUTICALS INC (INDEVUS PHARMACEUTICALS INC)
9.7.1 OVERVIEW
9.7.2 PRODUCTS & SERVICES
9.7.3 FINANCIALS
9.7.4 STRATEGY
9.7.5 DEVELOPMENTS
9.8 IPSEN
9.8.1 OVERVIEW
9.8.2 PRODUCTS & SERVICES
9.8.3 FINANCIALS
9.8.4 STRATEGY
9.8.5 DEVELOPMENTS
9.9 JOHNSON & JOHNSON
9.9.1 OVERVIEW
9.9.2 PRODUCTS & SERVICES
9.9.3 FINANCIALS
9.9.4 STRATEGY
9.9.5 DEVELOPMENTS
9.10 PFIZER INC
9.10.1 OVERVIEW
9.10.2 PRODUCTS & SERVICES
9.10.3 FINANCIALS
9.10.4 STRATEGY
9.10.5 DEVELOPMENTS
9.11 SANOFI-AVENTIS
9.11.1 OVERVIEW
9.11.2 PRODUCTS & SERVICES:
9.11.3 FINANCIALS
9.11.4 STRATEGY
9.11.5 DEVELOPMENTS
9.12 TEVA PHARMACEUTICAL INDUSTRIES LTD
9.12.1 OVERVIEW
9.12.2 PRODUCTS & SERVICES
9.12.3 FINANCIALS
9.12.4 STRATEGY
9.12.5 DEVELOPMENTS
9.13 TAKEDA PHARMACEUTICAL CO. LTD
9.13.1 OVERVIEW
9.13.2 PRODUCTS & SERVICES
9.13.3 FINANCIALS
9.13.4 STRATEGY
9.13.5 DEVELOPMENTS
9.14 OTHERS
9.14.1 FERRING PHARMACEUTICALS
9.14.1.1 OVERVIEW
9.14.1.2 PRODUCTS & SERVICES
9.14.1.3 FINANCIALS
9.14.1.4 STRATEGY
9.14.1.5 DEVELOPMENTS
9.14.2 TOLMAR INC
9.14.2.1 OVERVIEW
9.14.2.2 PRODUCTS & SERVICES
9.14.2.3 FINANCIALS
9.14.2.4 STRATEGY
9.14.2.5 DEVELOPMENTS

LIST OF TABLES

TABLE 1 GLOBAL PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 – 2020 ($MILLION)
TABLE 2 CHEMOTHERAPY MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($MILLION)
TABLE 3 CHEMOTHERAPY MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($MILLION)
TABLE 4 HORMONAL THERAPY MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($MILLION)
TABLE 5 HORMONAL THERAPY MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($MILLION)
TABLE 6 IMMUNOTHERAPY MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($MILLION)
TABLE 7 IMMUNOTHERAPY MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($MILLION)
TABLE 8 TARGETED THERAPY MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($MILLION)
TABLE 9 TARGETED THERAPY MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($MILLION)
TABLE 10 FIRMAGON MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 11 FIRMAGON MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 12 LUPRON MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 13 LUPRON MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 14 ZOLADEX MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 15 ZOLADEX MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 16 DECAPEPTYL MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 17 DECAPEPTYL MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 18 ELIGARD MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 19 ELIGARD MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 20 VANTAS MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 21 VANTAS MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 22 CASODEX MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 23 CASODEX MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 24 TAXOTERE MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 25 TAXOTERE MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 26 JEVTANA MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 27 JEVTANA MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 28 MITOXANTRONE MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 29 MITOXANTRONE MARKET REVENUE, BY GEOGRAPHY, 2005-2020 ($THOUSAND)
TABLE 30 EMCYT MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 31 EMCYT MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 32 PROVENGE MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 33 PROVENGE MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 34 ABIRATERONE ACETATE MARKET REVENUE , BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 35 ABIRATERONE ACETATE MARKET REVENUE, BY COUNTRY, 2015 - 2020 ($THOUSAND)
TABLE 36 MDV3100 MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 37 MDV3100 MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 38 TAK700 MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 39 TAK700 MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 40 LANREOTIDE MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 41 LANREOTIDE MARKET REVENUE, BY COUNTRY, 2015 - 2020 ($THOUSAND)
TABLE 42 TASQUINIMOD MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 43 TASQUINIMOD MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 44 ZALTRAP MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 45 ZALTRAP MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 46 CUSTIRSEN SODIUM MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 47 CUSTIRSEN SODIUM MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 48 SPRYCEL MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 49 SPRYCEL MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 50 IPILIMUMAB MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 51 IPILIMUMAB MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 52 PROSTATE CANCER DRUGS MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($MILLION)
TABLE 53 PROSTATE CANCER DRUGS MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($MILLION)
TABLE 54 NORTH AMERICA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 55 U.S: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 56 U.S: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 57 CANADA PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 58 CANADA: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 59 EUROPE: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 60 U.K: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 61 U.K: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 62 GERMANY: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 63 GERMANY: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 64 FRANCE: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY 2005 - 2020 ($THOUSAND)
TABLE 65 FRANCE: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 66 ITALY: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 67 ITALY: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 68 SPAIN: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 69 SPAIN: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 70 JAPAN: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 71 JAPAN: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 72 EMERGING MARKETS: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 73 BRAZIL: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 74 BRAZIL: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 75 RUSSIA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 76 RUSSIA: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 77 INDIA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 78 INDIA: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 79 CHINA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 80 CHINA: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 81 TURKEY: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 82 TURKEY: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 83 SOUTH KOREA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 84 SOUTH KOREA: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 85 KEY COMPANIES FOCUSING ON DEVELOPMENT OF PIPELINE DRUGS
TABLE 86 KEY COMPANIES FOCUSING ON COMMERCIALIZATION OF NEW PRODUCTS
TABLE 87 ACQUISITIONS & MERGERS, 2009 - 2011
TABLE 88 COLLABORATIONS/PARTNERSHIPS/AGREEMENTS/JOINT VENTURES, 2008 - 2011
TABLE 89 NEW PRODUCTS DEVELOPMENT, 2009 - 2011
TABLE 90 EXPANSION/NEW FACILITY/INVESTMENT, 2009
TABLE 91 FDA APPROVALS/GOVERNMENT GRANTS, 2008 - 2011
TABLE 92 PRECLINICAL STUDY, 2008 - 2011
TABLE 93 CLINICAL TRIALS - PHASE I
TABLE 94 CLINICAL TRIALS - PHASE II
TABLE 95 CLINICAL TRIALS - PHASE III
TABLE 96 NEW DRUG APPLICATION & MARKETING AUTHORIZATION APPLICATION, 2008 - 2011
TABLE 97 OTHERS, 2008 – 2011
TABLE 98 ABBOTT: SALES AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 99 ACTIVE BIOTECH: RESEARCH REVENUE AND R&D EXPENSES 2008 – 2010 ($MILLION)
TABLE 100 ASTRAZENECA PLC: R&D PIPELINE FOR PROSTATE CANCER TREATMENT
TABLE 101 ASTRAZENECA PLC: REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 102 ASTRAZENECA PLC: REVENUE, BY BUSINESS SEGMENTS, 2008 - 2010 ($MILLION)
TABLE 103 ASTRAZENECA PLC: REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
TABLE 104 ASTELLAS PHARMA INC: R&D PIPELINE FOR PROSTATE CANCER TREATMENT
TABLE 105 ASTELLAS PHARMA INC: REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 106 ASTELLAS PHARMA INC: SALES, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
TABLE 107 BRISTOL-MYERS SQUIBB: R&D PIPELINE FOR PROSTATE CANCER TREATMENT
TABLE 108 BRISTOL-MYERS SQUIBB: SALES AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 109 BRISTOL-MYERS SQUIBB: SALES, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
TABLE 110 BRISTOL-MYERS SQUIBB: REVENUE, BY BUSINESS SEGMENTS, 2008 - 2009 ($MILLION)
TABLE 111 DENDREON CORPORATION: REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 112 ENDO PHARMACEUTICALS INC: REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 113 ENDO PHARMACEUTICALS INC: REVENUE, BY BUSINESS SEGMENTS, 2008 - 2010 ($MILLION)
TABLE 114 IPSEN: R&D PIPELINE FOR PROSTATE CANCER TREATMENT
TABLE 115 IPSEN: REVENUE AND R&D EXPENDITURE, 2008 - 2010 ($MILLION)
TABLE 116 IPSEN: REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
TABLE 117 IPSEN: REVENUE, BY BUSINESS SEGMENTS, 2008 - 2010 ($MILLION)
TABLE 118 JOHNSON & JOHNSON: REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 119 JOHNSON & JOHNSON: REVENUE, BY BUSINESS SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 120 JOHNSON & JOHNSON: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($BILLION)
TABLE 121 PFIZER INC: REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 122 PFIZER INC: REVENUE BY BUSINESS SEGMENTS, 2008 - 2010 ($MILLION)
TABLE 123 PFIZER INC: REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
TABLE 124 SANOFI-AVENTIS: SALES AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 125 SANOFI-AVENTIS: SALES, BY BUSINESS SEGMENTS, 2008 - 2010 ($MILLION)
TABLE 126 SANOFI-AVENTIS: SALES, BY GEOGRAPHY, 2009 - 2010 ($MILLION)
TABLE 127 TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE AND R&D EXPENSES 2008 - 2010 ($MILLION)
TABLE 128 TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
TABLE 129 TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE, BY BUSINESS SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 130 TAKEDA PHARMACEUTICALS: REVENUE AND R&D EXPENSES, 2008 - 2011 ($MILLION)
TABLE 131 TAKEDA PHARMACEUTICALS: REVENUE, BY GEOGRAPHY, 2008 - 2011 ($MILLION)
TABLE 132 TAKEDA PHARMACEUTICALS: REVENUE, BY BUSINESS SEGMENTS, 2008 - 2010 ($MILLION)

LIST OF FIGURES

FIGURE 1 PROSTATE CANCER DISEASE OVERVIEW
FIGURE 2 PROSTATE CANCER ABSOLUTE INCIDENCE, BY COUNTRY, 2010 & 2020
FIGURE 3 PROSTATE CANCER INCIDENCE & MORTALITY (PER 100,000 MALES), BY COUNTRY, 2008
FIGURE 4 PROSTATE CANCER TREATMENT OPTIONS, BY STAGES
FIGURE 5 PROSTATE CANCER DRUGS: MARKET SEGMENTATION, BY THERAPY
FIGURE 6 CHEMOTHERAPY DRUGS: MARKET SEGMENTATION, BY DRUGS
FIGURE 7 HORMONAL THERAPY DRUGS: MARKET SEGMENTATION, BY DRUGS
FIGURE 8 IMMUNOTHERAPY DRUGS: MARKET SEGMENTATION, BY DRUGS
FIGURE 9 TARGETED THERAPY DRUGS: MARKET SEGMENTATION, BY DRUGS
FIGURE 10 PROSTATE CANCER TREATMENT OPTIONS, BY THERAPY
FIGURE 11 CHEMOTHERAPY MARKET SHARE, BY GEOGRAPHY, 2010 – 2020
FIGURE 12 HORMONAL THERAPY MARKET SHARE, BY GEOGRAPHY, 2010 – 2020
FIGURE 13 IMMUNOTHERAPY MARKET SHARE, BY GEOGRAPHY, 2015 & 2020
FIGURE 14 TARGETED THERAPY MARKET SHARE, BY GEOGRAPHY, 2015 & 2020
FIGURE 15 DISTRIBUTION OF GLOBAL R&D PROJECTS, BY THERAPEUTIC SEGMENTS, 2010 (%)
FIGURE 16 SUCCESS RATE IN CLINICAL TRIALS, BY CANCER TYPES
FIGURE 17 FAILURE RATE OF CANCER DRUGS VS NON CANCER DRUGS (PHASE WISE)
FIGURE 18 GROWING MALE POPULATION, 2010 – 2050
FIGURE 19 EXPENDITURE ON MEDICINES, BY GEOGRAPHY, 2010 VS 2015
FIGURE 20 MARKET REVENUE, BY TOP 10 THERAPEUTIC SEGMENTS ($BILLION)
FIGURE 21 MARKET SHARE, BY COMPANY, 2010 VS 2020 (%)
FIGURE 22 MARKET SHARE, BY GEOGRAPHY, 2010 VS 2020 (%)
FIGURE 23 MARKET SHARE, BY THERAPY, 2010 VS 2020 (%)
FIGURE 24 U.S: PREVALENCE & INCIDENCE OF PROSTATE CANCER, 2008 – 2020
FIGURE 25 U.S: CANCER CARE EXPENDITURES FOR TOP FIVE CANCER SITES, 2010 & 2020 ($BILLION)
FIGURE 26 U.S: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 27 CANADA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 28 U.K: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 29 GERMANY: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 30 FRANCE: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 31 ITALY: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 32 SPAIN: PROSTATE CANCER DRUGS MARKET, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 33 JAPAN: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 34 BRAZIL: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 35 RUSSIA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 36 INDIA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 37 CHINA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 38 TURKEY: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 39 SOUTH KOREA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 40 GROWTH STRATEGIES, 2008 - 2011
FIGURE 41 ACTIVE BIOTECH: PIPELINE PRODUCTS, BY THERAPY AREA, 2010
FIGURE 42 ASTRAZENECA PLC: SHARE OF BUSINESS SEGMENTS IN TOTAL REVENUE, 2009 – 2010 (%)
FIGURE 43 ASTRAZENECA PLC: SHARE OF GEOGRAPHIC REVENUE IN TOTAL REVENUE, 2009 VS 2010
FIGURE 44 ASTELLAS PHARMA INC: SHARE OF GEOGRAPHIC REVENUE IN TOTAL REVENUE, 2009 VS 2010
FIGURE 45 BRISTOL-MYERS SQUIBB: SHARE OF GEOGRAPHIC REVENUE IN TOTAL REVENUE, 2009 VS 2010 (%)
FIGURE 46 BRISTOL-MYERS SQUIBB: SHARE OF BUSINESS SEGMENTS IN TOTAL REVENUE, 2009 VS 2010 (%)
FIGURE 47 IPSEN: SHARE OF GEOGRAPHIC REVENUE IN TOTAL REVENUE, 2009 VS 2010
FIGURE 48 JOHNSON & JOHNSON: SHARE OF BUSINESS SEGMENTS IN TOTAL REVENUE, 2009 VS 2010
FIGURE 49 PFIZER INC: SHARE OF BUSINESS SEGMENTS IN TOTAL REVENUE, 2009 VS 2010 (%)
FIGURE 50 SANOFI-AVENTIS: SHARE OF BUSINESS SEGMENTS IN TOTAL REVENUE, 2009 VS 2010
FIGURE 51 SANOFI-AVENTIS: SALES, BY GEOGRAPHY 2009 VS 2010 ($MILLION)
FIGURE 52 TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE, BY GEOGRAPHY, 2009 VS 2010 ($MILLION)
FIGURE 53 TEVA PHARMACEUTICAL INDUSTRIES LTD: SHARE OF BUSINESS SEGMENTS IN TOTAL SALES, 2009 VS 2010 (%)
FIGURE 54 TAKEDA PHARMACEUTICALS: REVENUE, BY GEOGRAPHY, 2009 - 2010 ($MILLION)